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one child Stage IV Burkitt's lymphoma succumbed to sepsis.
Conclusion: A signiﬁcant proportion of children with malignancy in the
developing world start treatment with under nutrition. Childrenwith mild
and moderate malnutrition show improvement in nutritional status with
nutritionist intervention. Children with severe under nutrition at the start
of therapy continue to be a challenge in the developing world. Nutritional
assessment by nutritionist throughout therapy for malignancy is essential
for appropriate nutrition intervention.
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WITH HAEMATOLOGICAL MALIGNANCIES UNDERGOING
CONVENTIONAL CHEMOTHERAPY: A LARGE STUDY FROM A REFERRAL
CANCER CENTRE IN INDIA
Subramaniam Ramanathan 1, Tushar Idhate 1, Seema Gulia 1, Sanjay
Biswas 2, Rohini Kelkar 2, Tushar Vora 1, Maya Prasad 1, Girish Chinnaswamy1,
Gaurav Narula 1, Brijesh Arora 1, Shripad Banavali 1. 1Department of Medical
Oncology (Pediatric), Tata Memorial Hospital, India; 2Department of
Microbiology, Tata Memorial Hospital, Mumbai, India
Background: There is paucity of data on CMV infection in haematological
malignancies in non-transplant settings, which is critical to plan timely
therapy and reduce morbidity and mortality.
Methods: Between January 2008 and November 2015, we screened all
children with haematolymphoid malignancies having unexplained fever,
prolonged cytopenia, hemophagocytic lymphohistiocytosis (HLH) or clin-
ical CMV disease, for CMV using RT-PCR. CMV-positive episodes were
analysed for clinical features and response to treatment.
Results: Seventy children had CMV infection. Of them, 61 (87%) had CMV
DNAemia and 9 (13%) had CMV disease. The primary diagnoses were ALL
(n¼59, 85%), AML (n¼2), NHL (n¼6), Hodgkin's lymphoma (HL, n¼2), and
CML (n¼1). The median age was 12 years. For ALL patients, CMV DNAemia
and disease occurred mostly during either consolidation (46%) or main-
tenance (36%) phase. The most common presenting feature of CMV
infection was unexplained fever without focus (n¼68, 97%). Of these, 37
(54.5%) had no associated cytopenias. All became afebrile at a median
ganciclovir duration of 3 days (range, 2-7 days). The rest (n¼31, 45.5%) had
unexplained fever with cytopenia, and all recovered after a variable period
of 3 to 28 days (median, 15 days). Two of them developed HLH and were
treated with HLH protocol along with antiviral therapy. For patients with
CMV viraemia, CMV titres became undetectable after amedian period of 17
days (range 7-34 days). Five had relapse of CMV-viraemia: two had com-
plete response and survived, while 3 died of primary malignancy during
CMV therapy. For the 9 with CMV disease, their primary diagnoses were
ALL (n¼6), AML (n¼1), HL (n¼1), and Burkitt's Lymphoma (n¼1). Disease
sites were chorioretinitis (n¼2), pneumonitis (n¼3), gastrointestinal dis-
ease (n¼2) and encephalitis (n¼1). In addition, one patient had both GI
infection and CMV encephalitis. After treatment with I.V. ganciclovir, 5
patients recovered fully, 2 died of CMV, one died of progressive primary
disease and one was lost to follow up. Out of the 2 children with cho-
rioretinitis, one had permanent visual deﬁcits while the other recovered
with normal vision.
Conclusion: CMV DNAemia and disease are common in children with
haematological malignancies on standard-dose therapy. ALL patients were
more commonly affected, usually during the consolidation phase of ALL
therapy. Most presented with unexplained fever with or without pro-
longed cytopenias. Approximately 15% can progress to HLH or CMV disease
if not detected in time. Timely detection and therapy with ganciclovir is
curative in most children.
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PROCEDURAL SEDATION IN PEDIATRIC ONCOLOGY e A RANDOMIZED
COMPARATIVE TRIAL OF KETAMINE e MIDAZOLAM COMBINATION VS
PROPOFOL
C. Varsha, Manas Kalra, Anita S. Bakshi, Geeta Mandhani, Amita
Mahajan. Apollo Center for Advanced Pediatrics, Indraprastha Apollo
Hospitals, Delhi, IndiaBackground: Procedural pain is a signiﬁcant quality of life issue in chil-
dren undergoing treatment for childhood cancer. Painful procedures are
therefore done under sedation wherever feasible. Ideal sedation should be
safe, effective, have prompt induction and smooth recovery. Both keta-
mine-midazolam and propofol are frequently used in this setting and have
been reported to be efﬁcacious. However, there are no published pro-
spective, randomized comparative trials (RCT) directly comparing these
two groups when performed by non- anesthesiologists.
Objective: To compare ketamine+midazolam (Group A) and propofol
(Group B) as sedative agents for intrathecal chemotherapy with regards to
efﬁcacy, side effect proﬁle, time to induction, time to recovery and
smoothness of recovery.
Methods: A partially-blinded, RCTwas conducted over a period of one year
between July 2015-July 2016 after institutional ethics committee approval.
Children aged 1-12 years requiring intravenous sedation for intrathecal
chemotherapy were included. Children with known cardiovascular or
respiratory disturbances, presence of neurological abnormalities and he-
patic/renal failure were excluded. Patients were allocated to the two
treatment arms using computer generated randomization tables after
obtaining written, informed consent. The initial doses used were, keta-
mine at 2mg/kg, midazolam at 0.2 mg/kg and propofol at 2.5mg/kg as per
standard recommendations. The patient, parents and the person analyzing
the data were blinded. Time to sedation, dose required for effective
sedation, depth of sedation (using Modiﬁed Ramsey scale), vital parame-
ters intra-procedure, time to recovery, smoothness of recovery and
emergence phenomenon were documented.
Results: One hundred and ﬁve patients were enrolled (Group A: 53, Group
B: 52). Seven patients had failure of sedation (all were in Group B). 9 pa-
tients in group A and 35 patients in group B required top up over and above
the initial administered doses. Mean time to sedation in group B was
shorter than in group A (p¼0.001).Mean heart rate in group A was higher
than in group B (p¼0.000). Transient drop in saturation was noted in 9
patients in group A and in 14 patients in group B. Mean depth of sedation
in group A was greater than in group B (p¼0.001). Mean time to recovery
in group B was shorter than in group A (p¼0.000). Emergence symptoms
were experienced by 29 patients in group A and 5 patients in group B
(p¼0.000)
Conclusion: Ketamine-Midazolam combination appears to be safer and
more effective. However, propofol has a signiﬁcantly faster onset, quicker
recovery with a smoother emergence from sedation, but at the recom-
mended initial doses it provides inadequate sedation.
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Gandhi Cancer Institute and Research Centre, New Delhi, India
Background: Central Venous access devices (CVADs) usage comprises an
integral component for management of childhood malignancies. The
purpose of this study was to evaluate our experience of CVADs with regard
to their feasibility, safety, and complications.
Material andmethods: A retrospective analysis of all CVADs [peripherally
inserted central catheter (PICCs), chemoports (port-a-cath) and Hickman
catheters]placed in Pediatric Oncology department of our institute from
June 2015 to May 2016, was done. All procedures were performed under
ultrasound guidance ± image intensiﬁer. Information was collected
regarding demographic details, catheter life (number of catheter days), and
adverse events (AE) [namelyinfection, blockage, extrusion, port-tip
migration and exit site skin excoriation]. Risk factors for AE were analysed
which included underlying disease, age of patient, type of CVAD and
number of catheter days.
Results: During the study interval, 147 CVADs were placed in 138 patients
with a median age of 7.5 years (range 10 months -18 years) and a male:
female ratio of 100:38. The CVADs included 117 PICCs, 23 chemoports and
7 Hickman catheters. Three patients who came only for PICC insertion
were excluded from analysis. The remaining 135 patients had a follow-up
of 151 median catheter days (range 8 e 375 days). Overall incidence of AE
was 0.828/1000 catheter days (19/22,924 catheter days).None of the
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Of 114PICCs analyzed in 106 children, median age was 7.5years (range 1-
18yrs); haematological malignancies constituted 78.3% (83/106).The me-
dian catheter life was 155.5days with a total of 17,941 catheter day-
s.Elective removal was done in 57% (65/114).Another 34 (29.8%).patients
are currently on therapy.Five patients (4.4%) were lost to follow up.Inci-
dence of AE was 0.725 per 1,000 catheter days. Removal due to AE was
required in 8.8% (10/114). AE included suspected infection (5/13), docu-
mented line infection (3/13; gram negative¼2, gram positive ¼1), acci-
dental extrusion (2/13), exit site skin necrosis (3/13) with AE incidence of
0.279, 0.167, 0.111 and 0.167per 1000 catheter days respectively.
Among 30 surgically implanted CVADs in 30 children, themedian agewas 6
years (10monthse 18 years).Solid tumors, hematological malignancies and
benign haematological diseases constituted 66.6% (20/30),16.7% (5/30)
and16.7% (5/30) respectively. All Hickman catheters were inserted in pa-
tients undergoing bone marrow transplant. Median CVAD life was 147 days
with a total of 4983 CVAD days. Elective removal was done in 26.6% (8/30),
treatment is ongoing in 56.6% (17/30).AE rate was 1.204 per 1,000 catheter
days (6/30) which included catheter tip migration in a left IJV chemoport
managed without removal. Reasons for catheter removal were suspected
infection (3/5), tunnel track infection in Hickman (1/5) and partial port
extrusion (1/5) with AE rates of 0.602,0.201 and 0.201per 1000 catheter
days respectively.None of the catheter tip cultures yielded any organisms.
Age, diagnosis and type of catheter were not statistically signiﬁcant but
number of catheter days was a statistically signiﬁcant predictor of AE
(P¼0.0063).
Conclusion: CVADs are a safe and a reliable method of securing vascular
access in children with malignancies.Tunnelled catheters have more
complications compared to PICC albeit with an acceptable and manage-
able incidence.TM_SC-1_V1.13
SPECTRUM OF RESPIRATORY VIRAL INFECTIONS IN CHILDREN WITH
CANCERS: EXPERIENCE FROM A TERTIARY CANCER CENTRE IN
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Objectives: Pattern of respiratory viral infections (RVI) in children with
cancers is not well characterized in India. We conducted this study to
determine the spectrum, incidence of fever-neutropenia, need for hospital
admission, economic burden, and outcome (concomitant bacterial in-
fections, need for ICU care, and death) of RVI in our pediatric-oncology
unit.
Methods: Data was collected retrospectively from July 2015-April 2016. All
children (<18-years) with symptoms of an upper respiratory tract infec-
tion (fever/cough/rhinorrhea) were included. Nasal and throat swabs were
collected in Hi-Viral transport medium and analyzed using duplex Real
Time PCR with Taqman Probes-Vi. Children with Inﬂuenza A/B received
oseltamivir; those with symptomatic Respiratory Syncitial Virus (RSV)
received ribavirin. All children with fever-neutropenia received intrave-
nous antibiotics as per unit protocol.
Results: 104 viral isolates were identiﬁed in 89 patients. Median age was
5.5-years (range: 1.4-17.8); 65% were males. Majority of the episodes (91%)
were in haemato-lymphoid malignancies. For children on treatment for
ALL, 35 (42%) were in intensive and 48 (58%) in non-intensive phase of
chemotherapy. Clinical features included: fever (89.5%), cough (71%), rhi-
norrhea (25%), chest-signs (25%), vomiting (12.5%), diarrhea (5.5%), rash
(2%). Commonest isolate was Inﬂuenza-A (36.5%) followed by RSV (22.1%),
Coronavirus (9.6%), Metapneumovirus (8.7%), Parainﬂuenza (8.7%), Inﬂu-
enza-B (6.7%), Adenovirus (1.9%) and Rhinovirus (1.9%). Multiple viruses
were found in 4 (3.8%). Hematological parameters at presentation
included: hemoglobin (median:9.9g%, IQR 8.7;11.1), platelet (me-
dian:1,41,605/mm3, IQR 60,000;1,95,750), neutrophil count (median:1962/
mm3; IQR 390;2446), lymphocyte count (median:1277/mm3, IQR
300;1155), Neutrophil:lymphocyte ratio (NLR) (median:3.5; IQR0.3-4.2).
Overall, 50% of episodes warranted admission; majority (88.5%) with fever-
neutropenia. Concomitant bacterial infection was documented in 11(10.5%) episodes, with Pseudomonas (5;45%) being the commonest isolate.
One died (0.9%) following Acinetobacter sepsis with RSV infection. Twenty-
ﬁve (54%) required empirical escalation of antibiotics due to persistent
fever-neutropenia; 7 (28%) had a proven bacterial isolate. Six/104 (5.7%)
children needed ICU admission; 5 (83%) had concomitant bacteremia
(p<0.001).Median duration of neutropenia was 12-days (range:1-47).
Median duration of hospital-stay was 8-days (range:1-35).Median cost of
admission was INR 22,466 (range:2,176-1,15,160).Cost and duration of stay
was signiﬁcantly more in children with concomitant bacteremia
(p¼0.002). Median cost for children with RVI and no bacteremia, whose
antibiotics were escalated empirically (median INR 60,217, IQR 41,131;
1,24,037), was signiﬁcantly higher than those who stayed on 1st-line an-
tibiotics (median INR 11,503, IQR 2,699;24,868) (p<0.001).
On univariate analysis, signiﬁcant predictor of bacteremia in RVI was low
hemoglobin (p¼0.01). Median hemoglobin in children with bacteremia
(8.4g%, IQR 6.6;9.8) was signiﬁcantly lower than those without bacteremia
(10g%; IQR 9;11.3; p¼0.06). Age (p¼0.8), gender (p¼0.5), underlying ma-
lignancy (p¼0.6), intensive chemotherapy (p¼0.1), neutrophil count
(p¼0.1), duration of neutropenia (p¼0.72), lymphocyte count (p¼0.9),
platelet count (p¼0.1) and NLR (p¼0.1), failed to predict bacteremia.
Conclusion: Documented RVI in children with cancers does not preclude
bacteremia. However, cost of care gets signiﬁcantly increased for children
with RVI and persistent fever-neutropenia, evenwith no bacteremia, when
empirically escalated to higher antibiotics as per protocol (p<0.001). A
prospective study is needed to analyze whether the protocol for antibiotic-
escalation can be better rationalized in this cohort.
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Introduction: Reavan in 1988 noted that several risk factors for car-
diovascular diseases commonly cluster together, and he recognised
them as a disease, named syndrome X, currently known as metabolic
syndrome.Metabolic syndrome is a group of disorders related to insulin
resistance, characterized clinically by central obesity, hyperglycemia,
dyslipidemia and hypertension. There is a growing body of evidence
indicating that pediatric cancer survivors are at a greater risk of
developing metabolic syndrome. We studied the prevalence of meta-
bolic syndrome in children with cancer who completed their treatment
and on follow up.
Methodology: All relevant past medical data (of the disease, treatment
and all events) were collected from the medical records.Tanner staging
was perfomred, Height was measured using a Harpenden stadiometer.
Weight/WAIST circumference were measured. The body mass index
(BMI) was calculated as weight (kg)/(height (m)2).BMI 90th centile as
per CDC chart was taken as abnormal. Blood pressure was measured on
the right arm of the patient. Presence of family history of diabetes, car-
diovascular diseases and hypercholesterolemia were taken. Fasting Blood
sugar, insulin, HbA1C, lipid proﬁle were done. We used IDF (International
diabetes federation) criteria to assess the metabolic syndrome among
cancer survivors. This study was approved by our university ethics
comittee.
Results: Seventy ﬁve children who fulﬁlled the inclusion criteria were
included in this study. Out of which 48 were males and 27 were females.
Among these, majority of children are treated for acute lymphoblastic
leukemia. 8.25% of total population satisﬁed the criteria of metabolic
syndrome. Age, gender, diagnosis, modality of treatment were not to be of
statistical signiﬁcance, however majority of children with metabolic syn-
drome are in adolescent group.
Conclusion:With the better care committed to childrenwith cancer even in
developing country, the survival rates are greatly improving and so meta-
bolic syndrome is becoming the major target for intervention in the follow
up of cancer survivors. As metabolic syndrome cannot treated by a single
drug therapy, it is necessary to have cancer survivors follow up screening.
